A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy

Trial Profile

A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Atacicept (Primary)
  • Indications IgA nephropathy; Proteinuria
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2018 Planned primary completion date changed from 17 Aug 2020 to 30 Jul 2020.
    • 20 Mar 2018 Planned number of patients changed from 100 to 30.
    • 16 Jan 2018 Planned End Date changed from 17 Jan 2020 to 17 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top